This large-scale longitudinal study investigates the relationship between Varicella-zoster virus (VZV) reactivation, commonly known as shingles or herpes zoster (HZ), and the risk of developing dementia. Analyzing health records from over 100 million individuals in the United States, the research demonstrates a consistent association after controlling for nearly 400 covariates. Key findings show that recurrent HZ episodes increase dementia risk, while vaccination against HZ (using both live-attenuated and recombinant vaccines) is associated with a significantly reduced risk compared to a control vaccine. The study further reveals that stronger vaccine protection correlates with greater dementia risk reduction, and the waning effectiveness of the live-attenuated vaccine over time is mirrored by a diminishing protective effect against dementia. These results strongly implicate VZV reactivation as a modifiable risk factor for dementia.
VZV Reactivation and Dementia Risk: Key Findings from a Large-Scale Study
Massive Data Analysis: The study is based on a retrospective analysis of the Optum electronic health records (EHR) database, covering over 100 million individuals in the U.S. between 2007 and 2023. It used advanced machine-learning matching to control for nearly 400 covariates, including demographics, comorbidities, and healthcare-seeking behaviors, to ensure robust comparisons.
Recurrent Shingles Increases Dementia Risk: Compared to individuals who had a single episode of herpes zoster (HZ or shingles), those who experienced multiple episodes had a 7-9% higher risk of being diagnosed with dementia over a 3-9 year follow-up period.
Shingles Vaccines Reduce Dementia Risk: Vaccination against HZ was associated with a substantial reduction in dementia risk. Compared to a control group receiving the pneumococcal vaccine (PPSV23), the live-attenuated zoster vaccine (ZVL) was linked to a 33% risk reduction, and two or more doses of the recombinant zoster vaccine (RZV) were linked to a 27% risk reduction at 3 years post-vaccination.
Stronger Protection Yields Greater Benefit: The study found a dose-dependent relationship. The more effective RZV vaccine was associated with an 18% lower risk of dementia compared to the older ZVL vaccine at 5 years. Furthermore, receiving two or more doses of RZV provided a greater reduction in dementia risk than receiving only a single dose.
Waning Vaccine Effectiveness Correlates with Dementia Risk: The protective effect of the ZVL vaccine against dementia was observed to wane over a period of approximately 10 years. This decline was highly correlated (Pearson’s R = 0.59) with the known waning protection of the vaccine against HZ, strongly suggesting that the dementia-delaying benefit is directly linked to the suppression of VZV reactivation.
Higher-Risk Groups Benefit More: Individuals with a higher baseline risk for shingles, such as females and the elderly, showed a more prominent reduction in dementia risk following vaccination. For example, females aged 80-89 who received multiple RZV doses had a 39% lower risk of dementia at 3 years, compared to 27% for the overall population.
Key Implication: The consistent findings across multiple analyses strongly suggest that Varicella-zoster virus (VZV) reactivation is a modifiable risk factor for dementia. This opens potential avenues for dementia prevention through vaccination and management of viral reactivation.